Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Companies With Customers - MOH, TAP, PROT, MCP by

Stock-PR Reporting


FREE Daily Stock Alerts From



Proteonomix, Inc. (OTC.BB:PROT) reported that Proteonomix has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases. Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.

Michael Cohen, President of Proteonomix, stated: "This is another step in the development of our intellectual property and getting StromaCel into the commercial market. The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks."

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site,, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (NYSE:CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.


Molina Healthcare, Inc. (NYSE:MOH) disclosed that Molina Healthcare will report its earnings for the third quarter and nine months ended September 30, 2010, after the market closes on Tuesday, October 26, 2010. Molina Healthcare's management will host a conference call and webcast to discuss the earnings release at 5:00 p.m. Eastern time on the same day. The number to call for the interactive teleconference is (212) 231-2939. A telephonic replay of the conference call will be available from 7:00 p.m. Eastern time on Tuesday, October 26, 2010, through 6:00 p.m. on Wednesday, October 27, 2010, by dialing (800) 633-8284 and entering confirmation number 21482029. A live broadcast of Molina Healthcare’s conference call will be available on Molina Healthcare's website,, or at A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

Molina Healthcare, Inc. provides quality and cost-effective Medicaid-related solutions to meet the health care needs of low-income families and individuals and to assist state agencies in their administration of the Medicaid program. Molina Healthcare's licensed health plans in California, Florida, Michigan, Missouri, New Mexico, Ohio, Texas, Utah, Washington, and Wisconsin currently serve approximately 1.5 million members, and our subsidiary, Molina Medicaid Solutions, provides business processing and information technology administrative services to Medicaid agencies in Idaho, Louisiana, Maine, New Jersey, and West Virginia, and drug rebate administration services in Florida.


Molson Coors Brewing Company (NYSE:TAP) and Grupo Modelo, S.A.B de C.V. announced that they have agreed on key terms that will make Molson Coors the distributor of the Modelo family of brands in the UK and Channel Islands, and Japan, effective January 2011. The announcement builds on the strong Molson Coors-Modelo relationship in Canada. Under the new agreement, Molson Coors’ organizations in the UK and Japan will be responsible for importing, selling and marketing the Modelo brands country-wide. Corona Extra accounts for 90% of the distribution of Grupo Modelo’s products in the UK. Other prominent brands in the Modelo portfolio include Coronita (210 ml bottles of Corona), Modelo Especial, Pacífico, and Negra Modelo.

Molson Coors Brewing Company is a leading global brewer delivering extraordinary brands that delight the world’s beer drinkers. Molson Coors Brewing brews, markets and sells a portfolio of leading premium brands such as Coors Light, Molson Canadian, Carling, Blue Moon, and Keystone Light across North America, Europe and Asia. Molson Coors Brewing operates in Canada through Molson Coors Canada; in the U.S. through MillerCoors; and in the U.K. and Ireland through Molson Coors UK.


Molycorp, Inc. (NYSE:MCP), the Western Hemisphere's only producer of rare earths, declared that one of the world’s leading experts in the design and manufacture of permanent rare earth magnets, which are integral to advanced wind turbines, hybrid vehicles, defense systems and computers, is re-joining Molycorp to help direct Molycorp's re-establishment of magnet manufacturing business in the U.S. Stan Trout, Ph.D., P.E., will join Molycorp as Director of Magnet Manufacturing on October 1, 2010. For the last ten years, Dr. Trout successfully ran Spontaneous Materials, a consultancy for the industry. He previously worked for Magnequench -- one of the last companies to make neodymium-iron-boron permanent rare earth magnets in the U.S. – as well as for Hitachi Magnetics, Crucible Magnetics, Recoma and Molycorp. Dr. Trout helped to pioneer the use of permanent rare earth magnets in early Magnetic Resonance Imaging (MRI) units as well as many other applications.

Colorado-based Molycorp, Inc. is the only rare earth oxide, or REO, producer in the Western Hemisphere and currently produces approximately 3,000 tons of commercial rare earth materials per year. Following the execution of Molycorp's “mine-to-magnets” strategy and completion of its modernization and expansion efforts at its Mountain Pass., Calif. processing facility in 2012, Molycorp expects to produce at a rate of 20,000 tons of REO equivalent per year and will offer a range of rare earth products, including high-purity oxides, metals, alloys, and permanent magnets.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).

Sign Up For Free Stock Alerts At


Be Sure To Visit


The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.